Septerna, Inc.
NASDAQ:SEPNBiotechnology
-$0.73 today
- Market cap
- $1.88B
- Beta
- 2.38
- P/E (TTM)
- -43.6
- EPS (TTM)
- -$0.81
Volume 0.30M
Average 0.32M
SEPN Accounts Receivables
Cash effect of the change in amounts owed by customers; growing receivables consume cash.
Septerna, Inc.NASDAQ: SEPN
Accounts Receivables · Q3 FY2026 · quarter ended Sep 2026
Accounts receivables dips below year-ago levels
Q3 FY2026 accounts receivables of $6.72M (cash outflow) fell 20.8% year over year, behind the +21.4% change in trailing-twelve-month accounts receivables. Sequentially, it rose 410.2% from the prior quarter.
Context
- Accounts receivables amounted to 22.2% of revenue in FY2025, up 20.3 pp from a year earlier.
- Accounts receivables increased in 1 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth recovers from -20.8% toward the trailing-twelve-month pace of +21.4%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Accounts Receivables history
USD · from the cash flow
- Latest · FY2025
- (10.19M) USD
- Year-over-year change
- -50825.0%
| Period | Period end | Accounts Receivables | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (10.19M) | -50825.0% |
| FY2024 | 2024-12-31 | (20K) | +86.8% |
| FY2023 | 2023-12-31 | (151K) | — |
| FY2022 | 2022-12-31 | 0 | — |
Accounts Receivables vs competitors
How SEPN compares with its peers on the latest reported figures
- SEPN's LTM Sep 2026 accounts receivables of $10.24M is the 3rd largest of the 7 companies compared; the peer median is $0.
- Its year-over-year change of +21.4% is the highest of 2, against a peer median of -100.0%.
- Accounts receivables amounts to 10.6% of revenue for SEPN, versus a peer median of 50.0%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jun 2026 | $100.3M | — | — | — | |
| LTM Mar 2026 | $20M | — | — | 100.0% | |
SEPNSepterna, Inc. | LTM Sep 2026 | $10.24M | +21.4% | — | 10.6% |
MBXMBX Biosciences, Inc. Common Stock | LTM Sep 2026 | $0 | — | — | — |
KLRAKailera Therapeutics, Inc. | FY2025 | $0 | — | — | — |
| LTM Mar 2026 | $0 | -100.0% | — | 0.0% | |
| LTM Mar 2026 | $0 | — | — | — | |
| Peer median (excluding SEPN) | $0 | -100.0% | — | 50.0% | |
Competitors are the stored peer set for SEPN. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|
| Net Income | (27.68M) | 4.18M | (71.8M) | (48.88M) |
| Depreciation & Amortization | 577K | 848K | 1.4M | 1.6M |
| Deferred Income Tax | 0 | 491K | (491K) | 0 |
| Stock-Based Compensation | 1.52M | 1.62M | 3.15M | 8.48M |
| Change in Working Capital | 1.75M | 926K | 248K | 162.78M |
| Accounts Receivables | 0 | (151K) | (20K) | (10.19M) |
| Inventory | 0 | 0 | 0 | 0 |
| Accounts Payables | 1.73M | (653K) | 723K | 6.6M |
| Other Working Capital | 20K | 1.73M | (455K) | 166.36M |
| Other Non-Cash Items | 530K | (46.79M) | 18K | (13.79M) |
| Operating Cash Flow | (23.3M) | (38.72M) | (67.47M) | 110.19M |
| Capital Expenditures | (1.29M) | (2.88M) | (2.1M) | (518K) |
| Acquisitions (Net) | 0 | 0 | 0 | 12.5M |
| Purchases of Investments | 0 | 0 | (213.39M) | (450.95M) |
| Sales of Investments | 0 | 0 | 32.27M | 209.62M |
| Other Investing Activities | 0 | 25M | 22.63M | 0 |
| Investing Cash Flow | (1.29M) | 22.12M | (160.6M) | (229.35M) |
| Debt Repayment | 0 | 0 | 0 | 0 |
| Common Stock Issued | 82K | 0 | 302.79M | 1.69M |
| Common Stock Repurchased | 0 | (1K) | (1K) | (1K) |
| Dividends Paid | 0 | 0 | 0 | 0 |
| Other Financing Activities | 0 | 0 | 52K | 0 |
| Financing Cash Flow | 30.05M | 74.52M | 377.78M | 1.69M |
| Effect of Forex Changes | 0 | 0 | 0 | 0 |
| Net Change in Cash | 5.46M | 57.92M | 149.71M | (117.47M) |
| Free Cash Flow | (24.59M) | (41.6M) | (69.57M) | 109.67M |
Septerna, Inc.
NASDAQ:SEPN
Intrinsic Alpha fair value
Locked
Current Price
$39.45
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.